UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K/A

Amendment No. 1

 

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2019

 

Or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                     

 

Commission file number 001-14053

 

Milestone Scientific Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

13-3545623

State or other jurisdiction of Incorporation or organization

 

(I.R.S. Employer Identification No.)

 

425 Eagle Rock Avenue, Roseland, NJ 07068

(Address of principal executive offices)

Registrant’s telephone number, including area code: 973-535-2717

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Symbol

Name of each exchange on which registered

Common Stock, par value $.001 per share

MLSS

NYSE American

 

Securities registered pursuant to section 12(g) of the Act:                    NONE

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    ☐ Yes    ☑ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    ☐ Yes    ☑ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    ☑ Yes    ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    ☑ Yes    ☐ No

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment of this Form 10-K.    ☑

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

Smaller reporting company

 

 

 

 

Emerging Growth Company

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes ☐   No ☑

 

As of June 28, 2019, the last business day of the registrants most recently completed second fiscal quarter, the aggregate market value of the common stock held by non- affiliates of the issuer was $15,368,647. This amount is based on the closing price of $.36 per share of the registrant's common stock as of such date, as reported on the NYSE American. As of March 30, 2020, the registrant has a total of 49,410,176 shares of Common Stock, par value $0.001 per share outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

None

 

 

 

EXPLANATORY NOTE

 

Milestone Scientific Inc. (the “Company” or “Milestone Scientific”) is filing this Amendment No. 1 on Form 10-K/A (this “Form 10-K/A”) pursuant to General Instruction G(3) to Form 10-K, which amends and supplements our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2020 (the “Form 10-K”). This Form 10-K/A updates the information contained in Part IV, Item 15 to file two new exhibits to this Form 10-K/A and to re-file required updated certifications under Section 302 of the Sarbanes-Oxley Act of 2002. Because no financial statements are contained within this Form 10-K/A, the Company is not including the individual certification pursuant to Section 302 regarding financial statements, regarding disclosure control procedures, or regarding internal controls over financial reporting. Additionally, because no financial statements are contained within this Form 10-K/A, the Company is not required to file the certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Except for the amendments described above, this Form 10-K/A does not modify or update the disclosures in, or exhibits to, the Form 10-K.

 

 

 

MILESTONE SCIENTIFIC INC.

Annual Report on Form 10-K/A

For Fiscal Year Ended December 31, 2019

 

TABLE OF CONTENTS

 

PART IV

 

 

    Item 15.

Exhibits and Financial Statement Schedules

1

     

SIGNATURES

 

3

 

 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

The following documents are filed as part of this Report:

 

1

Financial Statements. See Index to Financial Statements on page F-1.*

 

 

2

Financial Statement Schedule

 

Schedules are omitted because the information required is not applicable or the required information is shown in the consolidated financial statements or notes thereto.

 

 

3

Exhibits

 

Certain of the following exhibits were filed as Exhibits to previous filings filed by Milestone Scientific under the Securities Act of 1933, as amended, or reports filed under the Securities and Exchange Act of 1934, as amended, and are hereby incorporated by reference.

 

Exhibit No

Description

 3.1

Restated Certificate of Incorporation of Milestone filed on September 6, 2013 (6)

 3.2

Form of Certificate of Designation filed on April 18, 2014 (7)

 3.3

Certificate of Correction to the Certificate of Designation filed on May 12, 2014 (8)

3.4

Certificate of Amendment to Restated Certificate of Incorporation**

 3.5

Amended and Restated By-laws of Milestone  filed April 1, 2019

 4.1

Specimen stock certificate (1)

4.3

Form of Common Stock Purchase Warrant issued in the 2016 Public Offering (11)

4.4

Form of Common Stock Purchase Warrant issued in the Feb. 2019 Public Offering (16)

4.5

Form of Common Stock Purchase Warrant issued in the Feb. 2019 Private Placement (17)

4.6

Description of Registrant's Securities**

10.1

Lease dated November 25, 1996 between Livingston Corporate Park Associates, L.L.C. and Milestone (2)

10.2

Lease amendment dated April 28, 2004 between Livingston Corporate Park Associates, L.L.C. And Milestone (3)

10.3

2011 Equity Compensation Plan (4)

10.4

Master Supply and Distribution Agreement, dated July 3, 2013, between Milestone Scientific Inc and Tri-anim Health Services, Inc (5)

 10.5

Agreement with Mark Hochman, dated July 2015 (8)

10.6

Investment Agreement, dated April 15, 2014, between Milestone Scientific Inc. and BP4 S.p.A. (7)

10.7

Exclusive Distribution and Supply Agreement, dated as of June 20, 2016, among Milestone Scientific Inc., Wand Dental, Inc. and Henry Schein, Inc. (9)

10.8ǂ

Amended and Restated Employment Agreement, dated December 1, 2016, between Wand Dental Inc. and Gian Domenico Trombetta (10)

10.9

Final Form of Asset Purchase Agreement, dated June 2, 2017, among APAD Octrooi B.V., APAD B.V., and Milestone Scientific Inc. (12)

10.10

Final form of the Memorandum of Agreement, dated June 6, 2017, between Solee Science & Technology U.S.A. Ltd. and Milestone Scientific Inc. (13)

10.11

Final form of the Promissory Note, dated June 6, 2017, in the principal amount of $1,275,000 made by Solee Science & Technology U.S.A. Ltd. to Milestone Scientific Ltd. (13)

10.12

Final form of the Stock Option Agreement, dated June 6, 2017, Solee Science & Technology U.S.A. Ltd. and Milestone Scientific Inc. (18)

10.13ǂ

New Employment Agreement between Milestone Scientific Inc. and Leonard Osser dated as of July 11, 2017. (14)

10.14ǂ

Employment Agreement between Milestone Scientific Inc. and Daniel Goldberger dated as of July 11, 2017. (14)

10.15ǂ

Covenant Agreement between Milestone Scientific Inc. and Daniel Goldberger dated and effective as of July 11, 2017. (14)

10.16ǂ

Consultant Agreement between Milestone Medical Inc. and U.S. Asian Consulting Group, LLC dated as of July 10, 2017. (15)

10.17

Underwriting Agreement, dated as of February 1, 2019 between Milestone Scientific Inc. and Maxim Group LLC, as underwriter (16)

10.18

Stock Purchase Agreement, dated as of February 8, 2019 between Milestone Scientific Inc. and BP4 S.p.A. (17)

21.1

List of Subsidiaries*

23.1

Consent of Friedman, LLP*

 

1

 

31.1

Rule 13a-14(a) Certification-Chief Executive Officer**

31.2

Rule 13a-14(a) Certification-Chief Financial Officer**

32.1

Section 1350 Certifications-Chief Executive Officer*

32.2

Section 1350 Certifications-Chief Financial Officer*

101.INS  

XBRL Instance Document*

101.SCH 

XBRL Taxonomy Extension Schema Document*

101.CAL 

XBRL Taxonomy Extension Calculation Linkbase Document*

101.LAB 

XBRL Taxonomy Extension Label Linkbase Document*

101.PRE  

XBRL Taxonomy Extension Presentation Linkbase Document*

101.DEF  

XBRL Taxonomy Extension Definition Linkbase Document*

*

Previously filed with Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the SEC on March 30, 2020.

**

Filed herewith.

   

ǂ

Indicates management contract or compensatory plan or arrangement.

 

 

1)

Incorporated by reference to Amendment No. 1 to Milestone Scientific’s Registration Statement on Form 10-KSB for the year ended May 15, 1995

 

2)

Incorporated by reference to Milestone Scientific’s Form 10-KSB for the year ended December 31, 1996.

 

3)

Incorporated by reference to Milestone Scientific’s Form 10-KSB for the year ended December 31, 2004.

 

4)

Filed as Appendix A to Milestone Scientific’s Proxy Statement filed with the SEC on May 2, 2011 and incorporated herein by reference.

 

5)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on July 9, 2013.

 

6)

Incorporated by reference to Milestone Scientific’s Form 10-K for the year ended December 31, 2013.

 

7)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on April 18, 2014.

 

8)

Incorporated by reference to Milestone Scientific’s Form 10-K for the year ended December 31, 2015.

 

9)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on June 30, 2016.

 

10)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on December 2, 2016.

 

11)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on December 16, 2016.

 

12)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on June 2, 2017.

 

13)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on June 7, 2017.

 

14)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on July 10, 2017.

 

15)

Incorporated by reference to Milestone Scientific’s Form 10-Q filed with the SEC on August 14, 2017.

 

16)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on February 1, 2019.

 

17)

Incorporated by reference to Milestone Scientific’s Form 8-K filed with the SEC on February 14, 2019.

 

2

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Milestone Scientific Inc.

 

 

By:

 

/s/ Joseph D’Agostino

 

 

Chief Financial Officer

 

 

 

 

 Date: April 2, 2020

 

3

 

 

 

Exhibit 3.4

 

 

CERTIFICATE OF AMENDMENT

OF

RESTATED CERTIFICATE OF INCORPORATION

OF

MILESTONE SCIENTIFIC INC.

 

The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify:

 

FIRST: That at a meeting of the Board of Directors of Milestone Scientific Inc. resolutions were duly adopted setting forth a proposed amendment of the Restated Certificate of Incorporation of said corporation, declaring said amendment to be advisable and calling a meeting of the stockholders of said corporation for consideration thereof. The resolution setting forth the proposed amendment is as follows:

 

RESOLVED, that the Restated Certificate of Incorporation of this corporation be amended by changing the Article thereof numbered “FOURTH” so that, as amended, said Article shall be and read as follows:

 

FOURTH: The total number of shares which this corporation shall have authority to issue is 80,000,000 shares, consisting of (i) 75,000,000 shares of common stock, $.001 par value per share (the “Common Stock”) and (ii) 5,000,000 shares of preferred stock, $.001 par value per share (the “Preferred Stock”). The Board of Directors, in the exercise of its discretion, is authorized to issue the undesignated Preferred Stock in one or more series, to determine the powers, preferences and rights, and qualifications, limitations or restrictions, granted to or imposed upon any wholly unissued series of undesignated Preferred Stock, and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by the stockholders.

 

SECOND: That thereafter, pursuant to resolution of its Board of Directors, the annual meeting of the stockholders of said corporation was duly called and held upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the amendment.

 

THIRD: That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

 

IN WITNESS WHEREOF, said corporation has caused this certificate to be signed this 19th day of December, 2019.

 

 

By: /s/ Joseph D’Agostino  

             Authorized Officer

 

Title: Chief Financial Officer

 

Name: Joseph D’Agostino 

 

 

 

 

Exhibit 4.6

 

Description of registrant's securities 

 

Common Stock

 

Our authorized capital stock includes 75,000,000 shares of common stock, par value $0.001 per share. As of March 31, 2020, there were 49,893,534 shares of common stock issued and outstanding, and 33,333 shares of common stock held in the treasury. The following description of the rights of the common stock do not apply to the treasury shares.

 

The holders of outstanding common stock are entitled to receive dividends out of assets legally available therefor at such times and in such amounts as the Board of Directors may from time to time determine. Each stockholder is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Directors are elected by plurality vote. Therefore, the holders of a majority of the common stock voted can elect all of the directors then standing for election. The common stock is not entitled to preemptive rights and is not subject to conversion. If we are liquidated or dissolved or our business is otherwise wound up, the holders of common stock would be entitled to share ratably in the distribution of all of our assets remaining available for distribution after satisfaction of all our liabilities and the payment of the liquidation preference of any outstanding preferred shares.

 

Authorized but Unissued Common Stock

 

The Delaware General Corporation Law does not require stockholder approval for any issuance of authorized shares, except in certain limited circumstances. However, the listing requirements of the NYSE American, which apply for so long as our common stock is listed on the NYSE American, require stockholder approval of certain issuances (other than a public offering) equal to or exceeding 20% of the then outstanding voting power or then outstanding number of shares of common stock, as well as for certain issuances of stock in compensatory transactions. We will not need to obtain stockholder approval for the issuance of the common stock to be sold in this offering. These additional shares may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions. One of the effects of the existence of unissued and unreserved shares of common stock may be to enable our Board of Directors to sell shares to persons friendly to current management, for such consideration, in form and amount, as is acceptable to the Board, which issuance could render more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive stockholders of opportunities to sell their common stock at prices higher than prevailing market prices.

 

Anti-Takeover Provisions

 

Delaware Law

 

We are subject to Section 203 of the DGCL. This provision generally prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date the stockholder became an interested stockholder, unless:

 

•     prior to such date, the board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

 

•     upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of voting shares outstanding those shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

 

•     on or subsequent to such date, the business combination is approved by the board of directors and authorized at an annual meeting or special meeting of stockholders and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.

 

Section 203 defines a business combination to include:

 

•     any merger or consolidation involving the corporation and the interested stockholder;

 

•     any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

 

 

 

•     subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

 

•     any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or

 

•     the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

 

In general, Section 203 defines an “interested stockholder” as any entity or person beneficially owning 15% or more of the outstanding voting stock of a corporation, or an affiliate or associate of the corporation and was the owner of 15% or more of the outstanding voting stock of a corporation at any time within three years prior to the time of determination of interested stockholder status; and any entity or person affiliated with or controlling or controlled by such entity or person.

 

These statutory provisions could delay or frustrate the removal of incumbent directors or a change in control of us. They could also discourage, impede, or prevent a merger, tender offer, or proxy contest, even if such event would be favorable to the interests of stockholders.

 

Certificate of Incorporation and Bylaw Provisions

 

Our certificate of incorporation and bylaws contain provisions that could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. In particular, the certificate of incorporation and bylaws, as applicable, among other things:

 

•     provide our board of directors with the ability to alter its bylaws without stockholder approval; and

 

•     provide that vacancies on our board of directors may be filled by a majority of directors in office, although less than a quorum.

 

Such provisions may have the effect of discouraging a third-party from acquiring us, even if doing so would be beneficial to our stockholders. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by them, and to discourage some types of transactions that may involve an actual or threatened change in control of us. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage some tactics that may be used in proxy fights. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our Company outweigh the disadvantages of discouraging such proposals because, among other things, negotiation of such proposals could result in an improvement of their terms. However, these provisions could have the effect of discouraging others from making tender offers for our shares that could result from actual or rumored takeover attempts. These provisions also may have the effect of preventing changes in our management.

 

Our certificate of incorporation provides that no director is personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty by such director as a director. Nonetheless, a director is liable to the extent provided by applicable law, (i) for breach of the director’s duty of loyalty to us or our stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL (relating to unlawful payment of dividend or unlawful stock purchase or redemption) or (iv) for any transaction from which the director derived an improper personal benefit. If the DGCL is amended to authorize the further elimination or limitation of the liability of directors, then the liability of one of our directors, in addition to the limitation on personal liability provided in our certificate of incorporation, will be limited to the fullest extent permitted by the amended DGCL. No amendment to or repeal of the relevant article of our certificate of incorporation will apply to or have any effect on the liability or alleged liability of any of our directors for or with respect to any acts or omissions of such director occurring prior to such amendment.

 

Our certificate of incorporation furthermore states that we shall indemnify, to the fullest extent permitted by Section 145 of the DGCL, as amended from time to time, each person that such section grants us the power to indemnify. Insofar as indemnification for liability under the Securities Act may be permitted for our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

 

 

Dividends

 

We have not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividends for the foreseeable future. We are not subject to any legal restrictions respecting the payment of dividends, except that we may not pay dividends if the payment would render us insolvent. Any future determination as to the payment of cash dividends on our common stock will be at our board of directors’ discretion and will depend on our financial condition, operating results, capital requirements and other factors that our board of directors considers to be relevant. Currently, the board of directors does not intend to pay any cash dividends, but retain all funds for working capital.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock and warrants is Continental Stock Transfer & Trust Company. 

 

 

 

 

 

Exhibit 31.1

 

 

Rule 13a-14(a)/15d-14(a) Certification

 

 I, Leonard Osser, the Interim Chief Executive Officer of Milestone Scientific Inc., certify that:

 

 

1.

I have reviewed this Amendment No. 1 to the annual report on Form 10-K of Milestone Scientific Inc. for the fiscal year ended December 31, 2019; and

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: April 2, 2020

 

/s/ Leonard Osser

Leonard Osser

Interim Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

Exhibit 31.2

 

 

Rule 13a-14(a)/15d-14(a) Certification

 

 

I, Joseph D'Agostino, the Chief Financial Officer of Milestone Scientific Inc., certify that:

 

 

1.

I have reviewed this Amendment No. 1 to the annual report on Form 10-K of Milestone Scientific Inc. for the fiscal year ended December 31, 2019; and

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: April 2, 2020

 

/s/ Joseph D'Agostino

Joseph D'Agostino

Chief Financial Officer

(Principal Financial Officer)